GlassScriptPhysician profile
Robert B Feldman
NPI 1467443564
$10,813.66
in general payments reported to CMS, 2019-2025
35 companies · $1,436 in 2025
The $1,436 reported for 2025 was more than what 84% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $646 · 2020: $1,998 · 2021: $663 · 2022: $672 · 2023: $3,287 · 2024: $2,112 · 2025: $1,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,693 · Consulting Fee: $2,115 · Honoraria: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,692.82 |
| Consulting Fee | $2,115.00 |
| Honoraria | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $2,944.71 | 2019-2025 | Susvimo, Vabysmo |
| Cardinal Health 108 LLC | $1,575.00 | 2020 | |
| Bausch & Lomb Americas INC. | $1,542.94 | 2022-2025 | Envista Mx60 Iol, Envista Aspire Iol, Envista Envy Iol |
| Genentech, INC. | $588.04 | 2019-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $581.75 | 2019-2023 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $517.79 | 2023-2025 | Izervay |
| Abbvie INC. | $397.73 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $334.79 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $327.85 | 2022-2025 | Syfovre |
| Mallinckrodt Hospital Products INC. | $230.18 | 2021-2025 | Acthar |
| Ivantis, INC | $203.70 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $196.53 | 2025 | Iluvien, Yutiq |
| Ocular Therapeutix, INC. | $190.65 | 2020-2025 | Dextenza |
| Alimera Sciences, INC. | $163.96 | 2021-2024 | Iluvien, Yutiq |
| Aerie Pharmaceuticals, INC. | $130.89 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $121.33 | 2019 | |
| Rxsight INC | $115.78 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Horizon Therapeutics Plc | $113.66 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $104.13 | 2019 | |
| Alcon Vision LLC | $87.28 | 2019-2025 | Clareon Panoptix Pro, Rocklatan, Eysuvis |
| Biotissue Holdings INC. | $72.71 | 2021-2023 | |
| Heidelberg Engineering, INC. | $57.46 | 2023-2024 | Spectralis |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $32.49 | 2019-2021 | |
| Oyster Point Pharma, INC. | $31.92 | 2022-2024 | Ryzumvi, Tyrvaya |
| Lumenis, INC | $26.24 | 2021 | |
| Sun Pharmaceutical Industries INC. | $21.95 | 2021 | |
| Biogen, INC. | $20.18 | 2022 | |
| Lensar, INC. | $19.12 | 2024 | Lensar Laser System |
| Halozyme INC | $19.08 | 2024 | Hylenex Recombinant |
| Johnson & Johnson Surgical Vision, INC. | $15.95 | 2022 | |
| Vertical Pharmaceuticals, LLC | $14.80 | 2019 | |
| Eyepoint US, INC. | $13.07 | 2023 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.